CN111629745A - 用于在手术前、期间或之后投与的glp-2类似物和肽体(peptibodies) - Google Patents

用于在手术前、期间或之后投与的glp-2类似物和肽体(peptibodies) Download PDF

Info

Publication number
CN111629745A
CN111629745A CN201880071791.3A CN201880071791A CN111629745A CN 111629745 A CN111629745 A CN 111629745A CN 201880071791 A CN201880071791 A CN 201880071791A CN 111629745 A CN111629745 A CN 111629745A
Authority
CN
China
Prior art keywords
glp
patient
surgery
peptibody
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880071791.3A
Other languages
English (en)
Chinese (zh)
Inventor
C·潘
A·诺顿
B·施特拉克-洛格
C·奥利维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Shire Nps Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Nps Pharmaceutical Co ltd filed Critical Shire Nps Pharmaceutical Co ltd
Publication of CN111629745A publication Critical patent/CN111629745A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880071791.3A 2017-11-06 2018-11-05 用于在手术前、期间或之后投与的glp-2类似物和肽体(peptibodies) Pending CN111629745A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762582055P 2017-11-06 2017-11-06
US62/582,055 2017-11-06
PCT/US2018/059175 WO2019090209A1 (en) 2017-11-06 2018-11-05 Glp-2 analogs and peptibodies for administration before during, or after surgery

Publications (1)

Publication Number Publication Date
CN111629745A true CN111629745A (zh) 2020-09-04

Family

ID=66332372

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880071791.3A Pending CN111629745A (zh) 2017-11-06 2018-11-05 用于在手术前、期间或之后投与的glp-2类似物和肽体(peptibodies)

Country Status (14)

Country Link
US (1) US11660328B2 (https=)
EP (1) EP3706774A4 (https=)
JP (2) JP7296958B2 (https=)
KR (1) KR102825098B1 (https=)
CN (1) CN111629745A (https=)
AR (1) AR113835A1 (https=)
AU (1) AU2018360744A1 (https=)
BR (1) BR112020008936A2 (https=)
CA (1) CA3079523A1 (https=)
IL (1) IL274098B2 (https=)
MX (1) MX2020004620A (https=)
TW (1) TWI911137B (https=)
WO (1) WO2019090209A1 (https=)
ZA (1) ZA202002080B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112912099A (zh) * 2018-10-24 2021-06-04 夏尔-Nps医药品有限公司 Glp-2融合多肽和用于治疗和预防胃肠病症的用途
WO2023001313A1 (zh) * 2021-07-20 2023-01-26 重庆派金生物科技有限公司 胰高血糖素样肽-2突变体的定向化学偶联物及其应用
CN117467025A (zh) * 2023-12-28 2024-01-30 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020003736A2 (pt) * 2017-08-22 2020-09-08 Shire-Nps Pharmaceuticals, Inc. polipeptídeos de fusão de glp-2 e usos para tratar e prevenir condições gastrointestinais
SG11202111311WA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
US20230129788A1 (en) * 2020-03-30 2023-04-27 Zealand Pharma A/S Glp-1/glp-2 dual agonists
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
WO2021263040A1 (en) * 2020-06-26 2021-12-30 Shire-Nps Pharmaceuticals, Inc. Stable peptibody formulations
WO2025181330A1 (en) * 2024-02-29 2025-09-04 Vectivbio Ag Dosage regimens for glucagon-like peptide 2 (glp-2) analogs

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050244A2 (en) * 2004-11-01 2006-05-11 Nps Allelix Corp. Treatment of short bowel syndrome patients with colon-in-continuity
US20070212355A1 (en) * 2005-10-24 2007-09-13 Baker Audrey E GLP-2 Mimetibodies, Polypeptides, Compositions, Methods and Uses
JP2009510999A (ja) * 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
JP2010502195A (ja) * 2006-08-31 2010-01-28 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
US20100113597A1 (en) * 2007-03-30 2010-05-06 Nobuhide Oshitani Pharmaceutical composition for prevention of progress of intestinal constriction associated with crohn's disease
WO2016108654A1 (ko) * 2014-12-31 2016-07-07 주식회사 제넥신 Glp 및 면역글로불린 하이브리드 fc 융합 폴리펩타이드 및 이의 용도
US20160310575A1 (en) * 2013-12-20 2016-10-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6206972B2 (ja) 2011-09-12 2017-10-04 アムニクス オペレーティング インコーポレイテッド グルカゴン様ペプチド−２組成物およびその作製法および使用法
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
KR101895047B1 (ko) 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050244A2 (en) * 2004-11-01 2006-05-11 Nps Allelix Corp. Treatment of short bowel syndrome patients with colon-in-continuity
JP2009510999A (ja) * 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
US20070212355A1 (en) * 2005-10-24 2007-09-13 Baker Audrey E GLP-2 Mimetibodies, Polypeptides, Compositions, Methods and Uses
JP2010502195A (ja) * 2006-08-31 2010-01-28 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
US20100113597A1 (en) * 2007-03-30 2010-05-06 Nobuhide Oshitani Pharmaceutical composition for prevention of progress of intestinal constriction associated with crohn's disease
US20160310575A1 (en) * 2013-12-20 2016-10-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
WO2016108654A1 (ko) * 2014-12-31 2016-07-07 주식회사 제넥신 Glp 및 면역글로불린 하이브리드 fc 융합 폴리펩타이드 및 이의 용도
CN107207618A (zh) * 2014-12-31 2017-09-26 格纳西尼有限公司 包含glp和免疫球蛋白杂合fc的融合多肽及其用途

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112912099A (zh) * 2018-10-24 2021-06-04 夏尔-Nps医药品有限公司 Glp-2融合多肽和用于治疗和预防胃肠病症的用途
WO2023001313A1 (zh) * 2021-07-20 2023-01-26 重庆派金生物科技有限公司 胰高血糖素样肽-2突变体的定向化学偶联物及其应用
CN117467025A (zh) * 2023-12-28 2024-01-30 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
WO2025140491A1 (zh) * 2023-12-28 2025-07-03 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用

Also Published As

Publication number Publication date
RU2020118172A (ru) 2021-12-08
JP7296958B2 (ja) 2023-06-23
JP7752152B2 (ja) 2025-10-09
AU2018360744A1 (en) 2020-05-07
MX2020004620A (es) 2020-10-12
IL274098A (en) 2020-06-30
IL274098B1 (en) 2024-08-01
EP3706774A4 (en) 2021-09-08
EP3706774A1 (en) 2020-09-16
BR112020008936A2 (pt) 2020-10-20
AR113835A1 (es) 2020-06-17
ZA202002080B (en) 2025-11-26
CA3079523A1 (en) 2019-05-09
US11660328B2 (en) 2023-05-30
JP2021502389A (ja) 2021-01-28
WO2019090209A1 (en) 2019-05-09
IL274098B2 (en) 2024-12-01
KR20200085763A (ko) 2020-07-15
TW201922279A (zh) 2019-06-16
JP2023107883A (ja) 2023-08-03
US20210169986A1 (en) 2021-06-10
KR102825098B1 (ko) 2025-06-26
TWI911137B (zh) 2026-01-11

Similar Documents

Publication Publication Date Title
JP7752152B2 (ja) 手術前、手術中または手術後に投与するためのｇｌｐ－２類似体及びｇｌｐ－２ペプチボディ
AU2021203106B2 (en) Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
RU2606840C2 (ru) Композиция для лечения диабета, содержащая конъюгат инсулина длительного действия и конъюгат инсулинотропного пептида длительного действия
TWI630214B (zh) 長效胰島素及胰促泌素肽之液體製劑
JP6076902B2 (ja) 新規な持続型グルカゴン結合体およびこれを含む肥満の予防および治療用薬学的組成物
CN109810198B (zh) 利用免疫球蛋白片段的位点特异性glp-2缀合物
TW201817741A (zh) 新穎胰島素類似物及其用途
TW202140065A (zh) 包含長效胰島素類似物接合物及長效促胰島素肽接合物之治療糖尿病組成物
TW201524995A (zh) ＩＬ－２２多肽及ＩＬ－２２Ｆｃ融合蛋白質及其使用方法
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
TW201920242A (zh) Glp-2融合多肽及用於治療及預防胃腸病症之用途
CN116098989A (zh) Fgf21变体、融合蛋白及其应用
AU2016332062A1 (en) Treatment of bile acid disorders
TW202317607A (zh) 融合蛋白及其應用
RU2795594C2 (ru) Пептитело glp-2 для введения до, в течение или после хирургического вмешательства
HK40037000A (en) Glp-2 analogs and peptibodies for administration before during, or after surgery
WO2024141054A1 (zh) 包含融合蛋白的药物组合物及其用途
CN108601819B (zh) 用死亡受体激动剂改善系统性硬化症
HK1238162A1 (en) Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40037000

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20221222

Address after: Massachusetts

Applicant after: Takeda Pharmaceutical Industry Co.,Ltd.

Address before: Massachusetts

Applicant before: Shire NPs Pharmaceutical Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230605

Address after: Osaka, Japan

Applicant after: TAKEDA PHARMACEUTICAL CO.,LTD.

Address before: Massachusetts

Applicant before: Takeda Pharmaceutical Industry Co.,Ltd.

TA01 Transfer of patent application right